InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,722.26
(
-0.19%
)
US TECH 100
19,517.20
(
0.53%
)
Dow Jones
41,914.75
(
-0.70%
)
Brent Oil
73.02
(
-0.23%
)
Bitcoin
63,217.86
(
0.15%
)
Post# of 253223
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120501
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 213943

Monday, 10/30/2017 10:15:23 AM

Monday, October 30, 2017 10:15:23 AM

Post# of 253223
NVS acquires AAAP for $82/ADS—a 44% premium to AAAP’s Nasdaq closing price on 9/27/17 (the day before it was reported that NVS might buying the company):

https://www.novartis.com/news/media-releases/novartis-announces-planned-acquisition-advanced-accelerator-applications

AAAP has an approved radiotherapy called Lutathera for rare GI and pancreatic cancers.

The nominal deal value is $3.9B. NVS plans to initiate a tender offer and will complete the buyout if ≥80% of AAAP shares are tendered.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up